Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | TACR1 | P25103 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13002270 | 1.00 | TSHR (0.52) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL7863791 | 1.00 | TSHR (0.52) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL14453899 | 0.92 | TSHR (0.61) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL7604498 | 0.83 | AGXT (0.44) | KMT2ACA1CA2CA9TACR1 | |
| SCHEMBL13246484 | 0.83 | TSHR (0.50) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL10052366 | 0.82 | TSHR (0.54) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL12519871 | 0.82 | TSHR (0.54) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL12519869 | 0.82 | TSHR (0.54) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL13003073 | 0.82 | TSHR (0.54) | TSHRKMT2ACA1CA2CA7 | |
| SCHEMBL1013889 | 0.81 | IDO1 (0.42) | KMT2ACA1CA2TACR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957228-B2 | Macrolide compound having anticancer effect | TOHOKU UNIVERSITY (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20130281714-A1 | MACROLIDE COMPOUND HAVING ANTICANCER EFFECT | TOHOKU UNIVERSITY (JP) | 2013-10-24 | — | — | US | disclosed |
| US-20120108564-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281714-A1 | MACROLIDE COMPOUND HAVING ANTICANCER EFFECT | HDAC6, RPL21, MKI67 | TSHR 4136/4885KMT2A 1987/4885CA1 4334/4885 |
| US-20120108564-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyradine Derivatives and Use Thereof as HIV Integrase Inhibitor | IMPDH1, IMPA1, DPYD | TSHR 4656/4885KMT2A 482/4885CA1 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.